BusinessMoneycontrol
Why Indian pharma isn't panicking on Trump's threat of 200% tariff on generics
in5points
Indian pharma companies are not panicking over Trump's threat of 200% tariffs on generics.
Most major Indian pharma companies have manufacturing presence in the US.
A two-year reprieve is expected to be enough for companies to comply if US pushes for reshoring.
Market awaits clarity on the tariff proposal.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Moneycontrol
Center-right
Mixed factuality
